Identification of Pharmacological Modulators of HMGB1-Induced Inflammatory Response by Cell-Based Screening

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gerö, Domokos ^a   Szoleczky, Petra ^a   Módis, Katalin ^a   Pribis, John P ^b   Al Abed, Yousef ^c   Yang, Huan ^c   Chevan, Sangeeta ^c   Billiar, Timothy R ^b   Tracey, Kevin J ^c   Szabo, Csaba ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; BUDESONIDE; DEXAMETHASONE; FENOTEROL; FLUDROCORTISONE; FLUMETASONE; GLUCOCORTICOID; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; I KAPPA B; IMIPENEM; INDAPAMIDE; INDINAVIR; MESSENGER RNA; METHYLPREDNISOLONE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; ORCIPRENALINE; PARTHENOLIDE; PREDNISOLONE; PROPRANOLOL; RITODRINE; SALBUTAMOL; TOLNAFTATE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; TYLOXAPOL; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL SCREENING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CATECHOLAMINES; CELL LINE; CELL SURVIVAL; DEXAMETHASONE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENERGY METABOLISM; GENE EXPRESSION; GLUCOCORTICOIDS; HMGB1 PROTEIN; INFLAMMATION MEDIATORS; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHORYLATION; PREDNISOLONE; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84879129201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065994     Document Type: Article

References (31)

1. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A, (2008) HMGB1: endogenous danger signaling. Mol Med 14: 476-84.
2. Harris HE, Andersson U, Pisetsky D, (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8: 195-202.
3. Andersson U, Tracey KJ, (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29: 139-62.
4. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, et al. (2010) High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285: 39888-97.
5. Lu B, Nakamura T, Inouye K, Li J, Tang Y, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-4.
6. Wang H, Ward MF, Sama AE, (2009) Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32: 348-57.
7. Yang H, Tracey KJ, (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 149-56.
8. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99: 12351-6.
9. Ditsworth D, Zong WX, Thompson CB, (2007) Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282: 17845-54.
10. Cai B, Chen F, Ji Y, Kiss L, de Jonge WJ, et al. (2009) Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation. J Cell Mol Med 13: 3774-85.
11. Schierbeck H, Wähämaa H, Andersson U, Harris HE, (2010) Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol Med 16: 343-51.
12. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 209: 1519-28.
13. Yang H, Lundbäck P, Ottosson L, Erlandsson-Harris H, Venereau E, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 18: 250-9.
14. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, et al. (2013) Signaling of High Mobility Group Box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med, in press.
15. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA. 107: 11942-11947.
16. Gero D, Modis K, Nagy N, Szoleczky P, Toth ZD, et al. (2007) Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay. Int J Mol Med 20: 749-61.
17. Gero D, Szoleczky P, Suzuki K, Modis K, Olah G, et al. (2013) Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. Diabetes 62: 953-64.
18. Lagathu C, Bastard JP, Auclair M, Maachi M, Kornprobst M, et al. (2004) Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 9: 911-20.
19. Ghio AJ, Marshall BC, Diaz JL, Hasegawa T, Samuelson W, et al. (1996) Tyloxapol inhibits NF-κB and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. Am J Respir Crit Care Med 154: 783-8.
20. Lahat A, Ben-Horin S, Lang A, Fudim E, Picard O, et al. (2008) Lidocaine down-regulates nuclear factor-κB signalling and inhibits cytokine production and T cell proliferation. Clin Exp Immunol 152: 320-7.
21. Park EA, Gurney AL, Nizielski SE, Hakimi P, Cao Z, et al. (1993) Relative roles of CCAAT/Enhancer-binding protein beta and cAMP regulatory element-binding protein in controlling transcription of the gene for phosphoenolpyruvate carboxykinase. J Biol Chem 268: 613-619.
22. Barnes PJ, (2002) Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19: 182-91.
23. Colangelo AM, Mallei A, Johnson PF, Mocchetti I, (2004) Synergistic effect of dexamethasone and beta-adrenergic receptor agonists on the nerve growth factor gene transcription. Brain Res Mol Brain Res. 124: 97-104.
24. Hori O, Brett J, Slattery T, Cao R, Zhang J, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-61.
25. Chen GY, Tang J, Zheng P, Liu Y, (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323: 1722-1725.
26. Bianchi ME, (2009) HMGB1 loves company. J Leukoc Biol 86: 573-576.
27. Selye H, (1971) Hormones and resistance. J Pharm Sci 60: 1-28.
28. Szelenyi J, Vizi ES, (2007) The catecholamine cytokine balance: interaction between the brain and the immune system. Ann N Y Acad Sci 1113: 311-24.
29. Tracey KJ, (2009) Reflex control of immunity. Nat Rev Immunol 9: 418-28.
30. Bertini R, Bianchi M, Ghezzi P, (1988) Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 167: 1708-12.
31. Szabo C, Hasko G, Zingarelli B, Nemeth ZH, Salzman AL, et al. (1997) Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 90: 95-100.